Mirzaie Vida, Eslaminejad Touba, Babaei Homayoon, Nematollahi-Mahani Seyed Noureddin
Department of Anatomy, Afzalipour School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Pharmaceutics Research Centre, Institute of Neuropharmacology, Kerman University of Medical Sciences, Kerman, Iran.
Drug Des Devel Ther. 2020 Sep 4;14:3589-3599. doi: 10.2147/DDDT.S260419. eCollection 2020.
Human butyrylcholinesterase (BChE) serves as a bio scavenger to counteract organophosphate poisoning. It is also a potential drug candidate in several therapeutic fields. Therefore, in the present study, we constructed a new dual-promoter plasmid consisting of (CMV) and human elongation factor 1α (EF-1α) promoters and transfected that into HEK-293 cells using Lipofectamine to enhance the BChE secretion.
The new dual-promoter construction (pBudCE dual BChE) including two copies of the gene was designed and transfected into cells by liposomal structures. The cloned plasmids were evaluated by enzyme digestion and gel electrophoresis analysis. Experimental groups were categorized into the cells transfected by pBudCE dual BChE (treatment), pCMV (positive control) vectors, and nontransfected cells (negative control). gene expression was evaluated by qRT-PCR and the enzyme activity was assessed using modified Ellman's method. The freeze-thaw process was carried out for analyzing the stability of the pBudCE dual BChE vector.
Validation examination of the cloned plasmids confirmed the successful cloning process. The gene expression level and Ellman's method value in pBudCE dual BChE was higher than the other groups. CMV promoter has also increased the enzyme activity, although the difference was not significant compared with the control group. Interestingly, freeze-thaw cycles followed by several passages did not affect the enzyme activity.
The designed construction with CMV and EF-1α promoters could increase BChE gene expression and the activity of the BChE enzyme in HEK-293 cell line. Large-scale production of BChE enzyme can be achieved by using dual-promoter plasmid construction compared to a single-promoter vector to be used in clinical trials.
人丁酰胆碱酯酶(BChE)作为一种生物清除剂可对抗有机磷中毒。它在多个治疗领域也是一种潜在的药物候选物。因此,在本研究中,我们构建了一种由巨细胞病毒(CMV)和人延伸因子1α(EF - 1α)启动子组成的新型双启动子质粒,并使用脂质体转染试剂将其转染至人胚肾293(HEK - 293)细胞中以增强BChE的分泌。
设计了包含两个 基因拷贝的新型双启动子构建体(pBudCE双BChE),并通过脂质体结构转染至细胞中。通过酶切和凝胶电泳分析对克隆的质粒进行评估。实验组分为用pBudCE双BChE转染的细胞(处理组)、pCMV转染的细胞(阳性对照组)和未转染的细胞(阴性对照组)。通过定量逆转录聚合酶链反应(qRT - PCR)评估 基因表达,并使用改良的埃尔曼方法评估酶活性。进行冻融过程以分析pBudCE双BChE载体的稳定性。
克隆质粒的验证检查证实了克隆过程的成功。pBudCE双BChE中的基因表达水平和埃尔曼方法值高于其他组。CMV启动子也提高了酶活性,尽管与对照组相比差异不显著。有趣的是,经过几次传代后的冻融循环并未影响酶活性。
设计的具有CMV和EF - 1α启动子的构建体可增加HEK - 293细胞系中BChE基因的表达和BChE酶的活性。与用于临床试验的单启动子载体相比,使用双启动子质粒构建体可实现BChE酶的大规模生产。